News

The Phase 2b  Pronto study did not meet its primary or secondary endpoints. A phase 3 Vital Amyloidosis study is also being discontinued based on futility analysis. AL amyloidosis is a

Zymeworks president & CEO Ali Tehrani said: “The team at Celgene has made excellent progress developing bispecific and multifunctional therapeutic candidates built on our industry-leading Azymetric platform and

Pfizer said that the additional requested information asked in the Complete Response Letter (CRL) sent by the US regulator is not related to safety or clinical data submitted

The partnership will use Biogen’s expertise in neuroscience research and drug development and Ionis’ capabilities in RNA targeted therapies to develop a range of investigational therapies. As per

The settlement also resolves claims asserted by Dicerna in a lawsuit against Alnylam in the United States District Court for the District of Massachusetts. Each party has agreed

The 18-month project has been made possible through the award of a £235,000 grant, part of the medicines manufacturing competition from Innovate UK. One of the current challenges

The German healthcare firm alleged that its independent investigation found material breaches of US Food and Drug Administration (FDA) integrity requirements relating to Akorn’s product development activities. The

Helperby also presented preclinical data which shows that AZT is active against carbapenem and colistin resistant Enterobacteriaceae. AZT is a DNA chain terminator and represents a new class

This investment brings the total Tmunity Series A financing to $135 million. Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell